JP2021502829A5 - - Google Patents

Download PDF

Info

Publication number
JP2021502829A5
JP2021502829A5 JP2020544387A JP2020544387A JP2021502829A5 JP 2021502829 A5 JP2021502829 A5 JP 2021502829A5 JP 2020544387 A JP2020544387 A JP 2020544387A JP 2020544387 A JP2020544387 A JP 2020544387A JP 2021502829 A5 JP2021502829 A5 JP 2021502829A5
Authority
JP
Japan
Prior art keywords
promoter
antigen
item
cells
immune
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2020544387A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021502829A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2018/061003 external-priority patent/WO2019099483A1/en
Publication of JP2021502829A publication Critical patent/JP2021502829A/ja
Publication of JP2021502829A5 publication Critical patent/JP2021502829A5/ja
Pending legal-status Critical Current

Links

JP2020544387A 2017-11-14 2018-11-14 Il−36を分泌する免疫応答性細胞およびその使用 Pending JP2021502829A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762585879P 2017-11-14 2017-11-14
US62/585,879 2017-11-14
PCT/US2018/061003 WO2019099483A1 (en) 2017-11-14 2018-11-14 Il-36 secreting immunoresponsive cells and uses thereof

Publications (2)

Publication Number Publication Date
JP2021502829A JP2021502829A (ja) 2021-02-04
JP2021502829A5 true JP2021502829A5 (https=) 2021-12-23

Family

ID=66538783

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020544387A Pending JP2021502829A (ja) 2017-11-14 2018-11-14 Il−36を分泌する免疫応答性細胞およびその使用

Country Status (7)

Country Link
US (2) US11766474B2 (https=)
EP (1) EP3710020A4 (https=)
JP (1) JP2021502829A (https=)
CN (1) CN111655270A (https=)
AU (2) AU2018367452B2 (https=)
CA (1) CA3082570A1 (https=)
WO (1) WO2019099483A1 (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3710020A4 (en) * 2017-11-14 2021-06-23 Memorial Sloan-Kettering Cancer Center IL-36 SECRETING IMMUNE RESPONSIVE CELLS AND USES THEREOF
EP4013857A1 (en) * 2019-08-13 2022-06-22 King's College London Immunoresponsive cells armoured with spatiotemporally restricted activity of cytokines of the il-1 superfamily
WO2021055731A1 (en) * 2019-09-20 2021-03-25 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Il-36 cytokine expressing oncolytic viruses for treating cancer
KR20210058038A (ko) 2019-11-13 2021-05-24 (주)아모레퍼시픽 인터루킨-36 감마를 포함하는 피부 미백용 조성물
CN115701999A (zh) * 2020-07-09 2023-02-14 南京传奇生物科技有限公司 用白介素-36工程化γδT细胞用于免疫疗法
CN112358539A (zh) * 2020-11-16 2021-02-12 桂林医学院附属医院 一种小鼠截短IL-36γ蛋白及其制备方法
WO2022116877A1 (en) 2020-12-02 2022-06-09 Shanghai Henlius Biotech, Inc. ANTI-GARP/TGFβ ANTIBODIES AND METHODS OF USE
CN114934071B (zh) * 2021-04-30 2023-10-17 四川大学华西医院 一种表达免疫调节因子的car载体及其应用
US20240424096A1 (en) * 2021-08-24 2024-12-26 Ecole Polytechnique Federale De Lausanne (Epfl) IL-10 Expressing Cells For Enhanced Cancer Immunotherapies
JP2025501522A (ja) 2021-12-17 2025-01-22 シャンハイ・ヘンリウス・バイオテック・インコーポレイテッド 抗ox40抗体及び使用方法
CN118488965A (zh) 2021-12-17 2024-08-13 上海复宏汉霖生物技术股份有限公司 抗ox40抗体、多特异性抗体及其使用方法
JP2025514610A (ja) 2022-03-25 2025-05-09 シャンハイ・ヘンリウス・バイオテック・インコーポレイテッド 抗msln抗体及び使用方法

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5091513A (en) 1987-05-21 1992-02-25 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
US5132405A (en) 1987-05-21 1992-07-21 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
JPS6412935A (en) 1987-07-02 1989-01-17 Mitsubishi Electric Corp Constant-speed travel device for vehicle
US5399346A (en) 1989-06-14 1995-03-21 The United States Of America As Represented By The Department Of Health And Human Services Gene therapy
US6436703B1 (en) 2000-03-31 2002-08-20 Hyseq, Inc. Nucleic acids and polypeptides
US7446190B2 (en) 2002-05-28 2008-11-04 Sloan-Kettering Institute For Cancer Research Nucleic acids encoding chimeric T cell receptors
US20130071414A1 (en) 2011-04-27 2013-03-21 Gianpietro Dotti Engineered cd19-specific t lymphocytes that coexpress il-15 and an inducible caspase-9 based suicide gene for the treatment of b-cell malignancies
AU2013327136A1 (en) * 2012-10-02 2015-04-16 Memorial Sloan-Kettering Cancer Center Compositions and methods for immunotherapy
PT2961831T (pt) * 2013-02-26 2020-10-12 Memorial Sloan Kettering Cancer Center Composições e métodos para imunoterapêutica
EP3783098A1 (en) * 2013-05-14 2021-02-24 Board Of Regents, The University Of Texas System Human application of engineered chimeric antigen receptor (car) t-cells
AU2015244039B2 (en) * 2014-04-07 2021-10-21 Novartis Ag Treatment of cancer using anti-CD19 chimeric antigen receptor
CA2945320A1 (en) * 2014-04-10 2015-10-15 Seattle Children's Hospital (dba Seattle Children's Research Institute) Drug regulated transgene expression
SI3227339T1 (sl) * 2014-12-05 2022-02-28 Memorial Sloan-Kettering Cancer Center Himerni antigenski receptorji, ki ciljajo na receptor, povezan z G-proteinom, in njihova uporaba
AU2015357526B2 (en) * 2014-12-05 2022-03-17 Eureka Therapeutics, Inc. Chimeric antigen receptors targeting B-cell maturation antigen and uses thereof
JP7115982B2 (ja) * 2015-10-30 2022-08-09 アレタ・バイオセラピューティクス・インコーポレイテッド 癌の治療のための組成物及び方法
EP3458474B1 (en) * 2016-05-18 2022-07-06 ModernaTX, Inc. Combinations of mrnas encoding immune modulating polypeptides and uses thereof
EP3710020A4 (en) * 2017-11-14 2021-06-23 Memorial Sloan-Kettering Cancer Center IL-36 SECRETING IMMUNE RESPONSIVE CELLS AND USES THEREOF

Similar Documents

Publication Publication Date Title
JP2021502829A5 (https=)
JP2021502828A5 (https=)
JP7755890B2 (ja) Car発現ベクター及びcar発現t細胞
JP2021513347A5 (https=)
IL314563A (en) Non-HLA-restricted T-cell receptors and their uses
US20240059754A1 (en) Chimeric antigen receptors and enhancement of anti-tumor activity
JPWO2019157454A5 (https=)
JP2016508728A5 (https=)
CN109689694B (zh) 与其受体IL-2Rβ结合的IL2作为用来增强自然杀伤细胞和调节性T细胞活性的平台
RU2015140811A (ru) Композиции и способы иммунотерапии
JP2017523784A5 (https=)
JPWO2020088631A5 (https=)
CA2425862A1 (en) Cd19-specific redirected immune cells
EP3870146A1 (en) Increase or maintaining t-cell subpopulations in adoptive t-cell therapy
Zhang et al. Genetic engineering with T cell receptors
US20230398216A1 (en) Chimeric activation receptors
Heiblig et al. Adoptive immunotherapy for acute leukemia: new insights in chimeric antigen receptors
EP4532727A2 (en) Compositions and methods comprising chimeric adaptor polypeptides
TW202309269A (zh) 重組抗原呈現細胞
Roeven et al. Immunotherapeutic approaches to treat multiple myeloma
Liegel et al. Cellular immunotherapy as a therapeutic approach in multiple myeloma
JPWO2022098925A5 (https=)
Cochlovius et al. Human melanoma therapy in the SCID mouse: In vivo targeting and reactivation of melanoma‐specific cytotoxic T cells by bi‐specific antibody fragments
Chaux et al. T‐cell co‐stimulation by the CD28 ligand B7 is involved in the immune response leading to rejection of a spontaneously regressive tumor
Zöller Unexpected induction of unresponsiveness by vaccination with transformed Salmonella typhimurium